Monica Heger tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb.
Natera has entered the oncology space with a ctDNA assay and sees its blood banking service as a way to eventually tap into the consumer genomics space.
The startup is currently fundraising in order to build out its CLIA-certified lab and run the clinical trials necessary to launch a lung cancer diagnostic.
Quest's QHerit will screen for 22 disorders and is based on recommendations issued this year by the American College of Obstetricians and Gynecologists.
Recently launched tests that screen for single-gene disorders are prompting questions about what is appropriate to screen for prenatally.
The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.
A UK-led international consortium is sequencing tuberculosis genomes and cataloguing drug resistance mutations to enable more rapid NGS-based diagnostics.
Genome.One's GoNavigate test will analyze the genetic risk for 49 disorders, as well as PGx variants related to more than 220 drugs.
The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology.
Karius has made its assay available to early-access users and is collaborating on several clinical trials to demonstrate its ability to diagnose infection.
Eric Schadt will serve as CEO of Sema4 and aims to move the company from genomic testing to an individualized and predictive health information firm.